| Dr Emil J Pecholt, DO | |
|
608 Nw 7th St, Pocahontas, IA 50574-1000 | |
| (712) 335-5632 | |
| Not Available |
| Full Name | Dr Emil J Pecholt |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 608 Nw 7th St, Pocahontas, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124099932 | NPI | - | NPPES |
| 838002300 | Medicaid | MN | |
| 1124099932 | Medicaid | IA | |
| P00710402 | Other | IA | RR MEDICARE - DC |
| P00725349 | Other | IA | RR MEDICARE - SG |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 33942 (Minnesota) | Secondary |
| 207Q00000X | Family Medicine | 2804 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Emil J Pecholt, DO 24 N 9th St, Suite A, Fort Dodge, IA 50501-3905 Ph: (515) 574-6890 | Dr Emil J Pecholt, DO 608 Nw 7th St, Pocahontas, IA 50574-1000 Ph: (712) 335-5632 |
News Archive
A world renowned expert in obesity research will be visiting Umeå University on Thursday 14 March, including holding a lecture in Aula Nordica. His main message to everyone is to "get up from your office chair."
Evogene Ltd., a leader in plant genomics underlying crop productivity for the food, feed and biofuel industries, today announced its financial results for the second quarter and half year ended June 30, 2013.
Worldwide Innovative Network (WIN) in personalized cancer medicine consortium today proudly announced that Pfizer, Inc (NYSE:PFE) is the first pharmaceutical company to become a member of the consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, and patient advocacy organizations working to make personalized cancer care a reality for patients worldwide.
A new in-vitro study by University of California, Davis, researchers indicates that quaternary ammonium compounds, or "quats," used as antimicrobial agents in common household products inhibit mitochondria, the powerhouses of the cell, as well as estrogenic functions in cells.
Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.
› Verified 9 days ago
Ted P George, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 608 Nw 7th St, Pocahontas, IA 50574 Phone: 712-335-5632 | |
Elizabeth Hemkens, FNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 22 3rd Ave Nw, Pocahontas, IA 50574 Phone: 712-335-7434 | |
Eugene Mullins, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 608 Nw 7th St, Pocahontas, IA 50574 Phone: 712-335-5632 | |
Jennifer E Boevers, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 608 Nw 7th St, Pocahontas, IA 50574 Phone: 712-335-5632 |